Tuesday, April 3, 2018

Cocrystal Pharma Receives FDA Clearance to Initiate Phase 2a Clinical Study Evaluating CC-31244 for Hepatitis C

Cocrystal Pharma Receives FDA Clearance to Initiate Phase 2a Clinical Study Evaluating CC-31244 for the Treatment of Hepatitis C Virus

ATLANTA, GA and BOTHELL, WA, April 03, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses and noroviruses, announced today that its Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) is now open and the Company is cleared to initiate its Phase 2a clinical study evaluating CC-31244 for the treatment of hepatitis C virus (“HCV”) infected individuals.

Gary Wilcox, Vice Chairman and Interim Chief Executive Officer of Cocrystal, commented, “The achievement of this regulatory milestone is a significant step forward in the advancement of our lead program, CC-31244. Based on the positive results from our Phase 1a/1b study, we believe that CC-31244 has the potential to change the treatment paradigm for patients living with HCV providing a shorter therapy with existing HCV combination therapies and a substantial and durable antiviral effect. We look forward to further evaluating the effect of CC-31244 and the commencement of this next phase of clinical development.”

CC-31244, the Company’s lead product in development, is an investigational, oral, highly potent, broad-spectrum non-nucleoside inhibitor with high barrier to drug resistance designed and developed using the Company's proprietary structure-based drug discovery technology. CC-31244 is active against all six HCV genotypes, with low level cytotoxicity in multiple cell types.

The Phase 2a study is an open-label study designed to evaluate the safety, tolerability and preliminary efficacy of CC-31244 with approved HCV drugs. Endpoints of the Phase 2a study include changes in HCV RNA viral load, adverse events and laboratory abnormalities. Cocrystal expects to commence its Phase 2a study of CC-31244 in the second quarter of 2018 and announce data in the fourth quarter of this year.

In August 2017, the Company announced positive data from the Phase 1a/1b trial of CC-31244 for the treatment of chronic hepatitis C infection. This randomized, placebo-controlled, double-blind Phase 1a/1b study evaluated single and multiple ascending doses of CC-31244 for safety/tolerability, pharmacokinetics, and antiviral activity in healthy volunteers and patients with HCV infection. In Phase 1a, 30 healthy volunteers received single doses (20-400 mg) of CC-31244, and 12 healthy volunteers received repeated doses of CC-31244 (either 200 or 400 mg) for 7 days. In Phase 1b, 15 patients with HCV genotype-1 infection received CC-31244 for 7 days (6, 400 mg daily; 6, 600 mg daily; 3, 200 mg twice daily). Eighteen subjects received placebo during the study.

As reported, there were no dose-limiting adverse events, study discontinuations due to adverse events, or serious adverse events. Viral load data showed that CC-31244 administered once daily (400 mg or 600 mg) or twice daily (200 mg) for 7 days had a substantial and durable antiviral effect, with an average HCV RNA viral load decline from baseline of 1000-fold by Day 4. Interestingly, the average viral load at 6 days after the last dose persisted in the range of 100-fold below baseline. HCV genotype 1b cell-based replicon assays using combinations of CC-31244 with other classes of HCV drugs showed additive and synergistic effects of CC-31244, providing important information for ultra-short therapy cocktail regimens.

No comments:

Post a Comment